Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates.
I
I
Millot
D
D
Plancade
M
M
Hosotte
C
C
Landy
J
J
Nadaud
C
C
Ragot
B
B
Graffin
C
C
Drouet
G
G
Kanny
D000368:Aged; D000799:Angioedema / Q000139:chemically induced / Q000188:drug therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D001920:Bradykinin / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007818:Laryngeal Diseases / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D020913:Perindopril / Q000009:adverse effects; D011719:Pyrazines / Q000009:adverse effects; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D001779:Blood Coagulation Factors; D054873:Dipeptidyl-Peptidase IV Inhibitors; D011719:Pyrazines; D014230:Triazoles; C025667:prothrombin complex concentrates; D001920:Bradykinin; D000068900:Sitagliptin Phosphate; D020913:Perindopril